Navigation Links
Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
Date:11/4/2008

Canadian companies team up in specialty biologics development

TORONTO and CHARLOTTETOWN, Nov. 4 /PRNewswire/ - BioVectra Inc. and Therapure BioPharma Inc. have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.

Over the past five years, BioVectra has been developing proprietary technologies for PEGylation as a mechanism for drug delivery. The partnership with Therapure builds upon BioVectra's expertise in the production of modified biologic molecules using a proprietary MPEG technology.

Therapure, from its 130,000 sq. ft facilities in Mississauga, Ontario, adds proprietary purification techniques and impressive formulation, fill, and finish expertise in biologics handling.

"We are very excited about working with BioVectra," said Thomas Wellner, President and CEO of Therapure Biopharma. "They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership."

"Our current program for drug development depends on finding the right partners," said Dale Zajicek, COO and VP of Business Development for BioVectra. "We know we have made a good choice in Therapure Biopharma and we look forward to working together to further the development and commercialization of this product."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: http://www.therapurebio.com

About BioVectra Inc.:

BioVectra Inc. is a growing Canadian biopharmaceutical company focused on contract manufacturing and product development of active pharmaceutical ingredients, pharmaceutical intermediates, and specialized bioreagents. Located in Prince Edward Island, BioVectra currently holds 8 Drug Master File filings and is an active supplier to most of the major pharmaceutical, biotechnology, and diagnostic companies in North America and Europe.

For more information, please visit: http://www.biovectra.com


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
2. Therapure Biopharma Inc. opens for business with first client contracts
3. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
6. CeNeRx BioPharma Completes $15 Million Series B Financing
7. Lilly Recognized as One of the Worlds Top Biopharmaceutical Employers
8. Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
9. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
10. Helix Biopharma Closes $11.4 Million Private Placement
11. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... WASHINGTON, DC, USA (PRWEB) , ... May 23, 2017 , ... ... the economy as well as an enabler of life-saving medical and other vital technologies ... and photonics . They joined others in the scientific community today in responding to ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... unlimited source of human cardiovascular cells for research and the development of ... it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying ...
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq Technology, a ... a facility expansion to accommodate its rapid growth. , The renovations at the ... renovation of the existing areas. The expansion includes, a state-of-the-art engineering facility, and ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop and ... downtown Boston at 745 Atlantic Ave. , “We are seeing that even the ... value they provide, not just to patients, but also payers. Having a presence in ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):